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Despite the recognized role of tumor necrosis factor (TNF) in
inflammation and neuronal degeneration, anti-TNF therapeutics
failed to treat neurodegenerative diseases. Animal disease models
had revealed the antithetic effects of the two TNF receptors (TNFR) in
the central nervous system, whereby TNFR1 has been associated with
inflammatory degeneration and TNFR2 with neuroprotection. We
here show the therapeutic potential of selective inhibition of TNFR1
and activation of TNFR2 by ATROSAB, a TNFR1-selective antagonistic
antibody, and EHD2-scTNFR2, an agonistic TNFR2-selective TNF, re-
spectively, in a mouse model of NMDA-induced acute neurodegener-
ation. Coadministration of either ATROSAB or EHD2-scTNFR2 into the
magnocellular nucleus basalis significantly protected cholinergic neu-
rons and their cortical projections against cell death, and reverted the
neurodegeneration-associated memory impairment in a passive
avoidance paradigm. Simultaneous blocking of TNFR1 and TNFR2 sig-
naling, however, abrogated the therapeutic effect. Our results un-
cover an essential role of TNFR2 in neuroprotection. Accordingly,
the therapeutic activity of ATROSAB is mediated by shifting the bal-
ance of the antithetic activity of endogenous TNF toward TNFR2,
which appears essential for neuroprotection. Our data also explain
earlier results showing that complete blocking of TNF activity by anti-
TNF drugs was detrimental rather than protective and argue for the
use of next-generation TNFR-selective TNF therapeutics as an effec-
tive approach in treating neurodegenerative diseases.
TNF | TNFR1 | TNFR2 | neuroprotection | neurodegeneration
Tumor necrosis factor (TNF) is a master proinflammatory cyto-kine that plays an important role in the initiation and orches-
tration of immunity and inflammation (1, 2). Elevated TNF levels
have been associated with different autoimmune diseases, and de-
regulation of TNF expression and signaling can lead to chronic
inflammation and tissue damage (3–6). Therefore, several anti-TNF
therapeutics are clinically approved and successfully used to treat
autoimmune diseases, such as rheumatoid arthritis, psoriasis, or
inflammatory bowel disease. Up-regulated TNF expression has also
been associated with different neurodegenerative diseases, e.g.,
Alzheimer’s disease, Parkinson’s disease, stroke, and multiple scle-
rosis (MS) (7). However, an anti-TNF therapeutic failed in a phase II
randomized, multicenter, placebo-controlled study for the treatment
of relapsing remitting MS (Lenercept study) because symptoms of
Lenercept-treated patients were significantly increased compared
with patients receiving placebo, and neurologic deficits tended to be
more severe in the Lenercept treatment groups (8). Next to induction
or aggravation of demyelinating diseases, all anti-TNF therapeutics
may induce severe side effects such as serious infections, including
reactivation of tuberculosis and invasive fungal and other opportu-
nistic infections. An increased susceptibility to develop additional
autoimmune diseases and lymphomas has also been reported (3).
The negative results of the Lenercept study and the observed
severe side effects of anti-TNF therapeutics in approved indications
might be explained by the pleiotropic actions of TNF, including
both pro- and antiinflammatory functions and other immune reg-
ulatory as well as regenerative activities. Blocking all effects of TNF
therefore might be counterproductive. Because most of the proin-
flammatory actions of TNF are mediated by TNFR1, a more ef-
fective therapeutic approach could be the selective blocking of
TNFR1 signaling; this would spare TNFR2 signaling, which has
been implicated in various protective and regenerative responses,
particularly in the central nervous system: TNFR2 signaling was
shown to promote neuronal survival and oligodendrocyte re-
generation in in vivo models of ischemic and neurotoxic insults (9,
10), respectively. Specific activation of TNFR2 rescues neurons (11)
and oligodendrocytes (12) from oxidative stress and promotes
oligodendrocyte differentiation and myelination (13, 14). In addition,
TNFR2 signaling protects neurons from glutamate-induced excito-
toxicity in vitro (15, 16).
Glutamate, a key neurotransmitter, can interact with the iono-
tropic AMPA and NMDA receptors. Exacerbated activation of
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these glutamate receptors may lead to progressive neuronal cell
death, which is a hallmark of acute and chronic neurological dis-
eases (17). Consequently, NMDA receptor antagonists such as
dizocilpine (MK-801) or memantine were developed and revealed
neuroprotective effects against ischemia-induced neuronal death
in vitro and ischemic brain damage in vivo (18, 19). However, in-
hibitors of NMDA receptors largely failed in clinical studies (20).
Because TNFR2 signaling protects neurons from glutamate-
induced excitatory cell death in vitro, ligands promoting TNFR2
signaling might be superior to NMDA antagonists because they
do not completely inhibit glutamate-induced signal transmission,
but buffer excitotoxicity likely by acquisition of a resistant state of
affected cells. Because of the antithetic action of TNF via its two
receptors, we reasoned that both an inhibition of TNFR1 signal-
ing and a selective activation of TNFR2 signaling, respectively,
could shift the balance of endogenous TNF activity toward an overall
neuroprotective/regenerative response. We here report on the thera-
peutic activity of the human TNFR1-selective antagonist ATROSAB
(21, 22) and a human TNFR2 selective agonist (EHD2-scTNFR2) in
in vitro and in vivo models of excitotoxic brain damage (23, 24) using
humanized TNFR1 and TNFR2 knock-in mice.
Results
Generation and Characterization of a TNFR2 Selective Agonist. Effi-
cient activation of TNFR2 requires receptor oligomerization by
the membrane form of TNF (tmTNF) or oligomerized soluble
forms of tmTNF mimicking receptor activation via tmTNF (11, 25)
such as a TNFR2-selective TNF mutein, fused to the trimerization
domain tenascin C (TNC–scTNFR2) recently developed by the au-
thors (11). We here describe a TNFR2-selective TNF mutein, which
consists of a covalently stabilized human TNFR2-selective (D143N/
A145R) (25) single-chain TNF (scTNFR2) fused to the dimeriza-
tion domain EHD2 derived from the heavy chain domain CH2 of
IgE (26), constituting a disulfide bonded dimer that is, with respect
to TNF domains, hexameric (EHD2–scTNFR2; Fig. 1A). The purity
of the recombinant protein was confirmed by SDS/PAGE and
Coomassie staining (Fig. 1B). Under reducing conditions, the TNF
variant exhibited an apparent molecular mass of ∼70 kDa, matching
the calculated molecular mass of 68.35 kDa. Under nonreducing
conditions the expected dimer of ∼130 kDa was observed (Fig. 1B).
The oligomerization state of EHD2–scTNFR2 was further charac-
terized by size exclusion chromatography (SEC; Fig. 1C). EHD2–
scTNFR2 eluted as a single major peak, indicating high purity.
TNF receptor selectivity of EHD2–scTNFR2 was analyzed by
binding studies with immobilized huTNFR1–Fc and huTNFR2–Fc
fusion proteins. Whereas EHD2–scTNFR2 did not interact with
huTNFR1, the fusion protein efficiently bound to huTNFR2 (Fig.
1D). In contrast, soluble human TNF (huTNF) efficiently bound to
huTNFR1, whereas it just weakly interacted with huTNFR2 (Fig.
1D). Furthermore, EHD2–scTNFR2 did not activate TNFR1-
dependent cell death in L929 (Fig. 1E), verifying that EHD2–scTNFR2
had lost affinity for TNFR1 due to the mutations D143N/A145R. In
contrast, EHD2-scTNFR2 efficiently induced cell death in Kym-1
cells, which endogenously express both TNF receptors and are
highly sensitive to endogenous TNF-induced TNFR1 mediated
cytotoxicity (27) (Fig. 1G). Interestingly, induction of cell death was
not enhanced by addition of the cross-linking TNFR2-specific mono-
clonal antibody 80M2, which in concert with soluble TNF is able
to mimic the action of tmTNF (11, 28). Differently, the bioactivity
of scTNFR2, a covalently stabilized huTNFR2-selective TNF tri-
mer, was strongly enhanced in the presence of 80M2 (Fig. 1G),
indicating that dimerization of scTNFR2 via EHD2 is necessary and
sufficient to fully activate huTNFR2.
ATROSAB and EHD2–scTNFR2 Are Neuroprotective in Vivo. To assess
both EHD2–scTNFR2 and ATROSAB in an in vivo model
of neurodegeneration, hu/mTNFR-knock-in mice (Figs. S1–S4)
were generated and used in the nucleus basalis lesion model. The
hu/mTNFR knock-in (k/i) mice express a chimeric TNFR, where
the extracellular part of the human receptor is fused to the trans-
membrane- and intracellular region of the mouse TNFR. This
chimeric hu/mTNFR was introduced into the germline of C57BL/6
mice by knock-in technology, replacing the endogenous mouse
TNFR, thereby using the regulatory elements from the wild-
type mouse TNFR; this should lead to an expression pattern
of the hu/mTNFR comparable to the wild-type mouse TNFR.
The expression and functionality of the chimeric hu/mTNFR
in hu/mTNFR-k/i mice was investigated using primary cells
isolated from different tissues and in vivo experiments. Using
primary immune cells, neurons, and mouse embryonic fibro-
blasts (MEFs), we demonstrated that expression of chimeric
hu/mTNFR1 and hu/mTNFR2 resemble the expression pattern
of the wild-type TNFRs (Figs. S5 and S6). Furthermore, we
demonstrated the functionality of the chimeric hu/mTNFRs
both using in vitro experiments with primary MEFs and thy-
mocytes as well as in vivo experiments showing TNF sensitivity
of hu/mTNFR1-k/i mice (Fig. S7).
By stereotactic NMDA injection, lesions in the nucleus basalis
magnocellularis (NBM) were generated. Lesioning of the NBM
resulted in a decrease of body weight (Fig. S8), reduction of
cholinergic fibers of the parietal cortex (Fig. 2 B and F), and
macrophage/microglial activation within the NBM (Fig. 2 D and
H and Fig. S9). These symptoms can be assessed to determine
the lesion size. Both EHD2–scTNFR2 and ATROSAB show a
strong protective effect in this in vivo model when simulta-
neously injected with NMDA into the NBM (Fig. 2 B, D, F, and
H and Fig. S9). Injection of a control IgG (anti-huEGFR),
however, did not significantly alter NMDA-mediated neuro-
degeneration (Fig. 2 F and H).
Fig. 1. Genetic engineering and bioactivity of EHD2–scTNFR2. (A) Schematic
representation of EHD2–scTNFR2. (B) Coomassie staining and immunoblot of
EHD2–scTNFR2 under reducing (column 1) and nonreducing (column 2) condi-
tions. (C) HPLC-SEC analysis of EHD2–scTNFR2 using a BioSep-Sec-2000 column.
Peak positions of relevant standard proteins are indicated. (D and E) Binding of
soluble huTNF (□) and membrane-TNF mimetic EHD2–scTNFR2 (●) to huTNFR1
(huTNFR1–Fc) or huTNFR2 (Etanercept; huTNFR2–Fc) was determined by ELISA
(n = 3; ±SEM). (F) L929 cells were cultivated with titrations of recombinant
human TNF (huTNF) or EHD2–scTNFR2. Cell viability was determined by crystal
violet staining (n = 4; mean ± SEM). (G) Kym-1 cells were stimulated with (open
symbols) or without (closed symbol) the TNFR2 cross-linking mAb 80M2 for
30 min at 37 °C. Then titrations of scTNFR2 (squares) or EHD2–scTNFR2 (circles)
were added and cells were incubated for 24 h. Cell viability was determined by
crystal violet staining (n = 4–6; mean ± SEM).
2 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1605195113 Dong et al.
ATROSAB and EHD2–scTNFR2 Improve Memory Performance in the
NBM Lesion Model. Memory was evaluated as parameter for the
protective effects of EHD2–scTNFR2 in the hu/mTNFR2-k/i
mice and ATROSAB in the hu/mTNFR1-k/i mice against
NMDA-induced neurotoxicity in the nucleus basalis and sub-
sequent cholinergic fiber loss in parietal cortex. The sequence of
memory tests performed in hu/mTNFR2-k/i and hu/mTNFR1-k/i
mice are depicted in Fig. 3A and in Figs. S10 and S11. The
NMDA-induced NBM lesion and the compounds tested had no
significant effect on short-term memory performance in the
spontaneous alternation task (Figs. S10B and S11B) or number
of entries recorded (Figs. S10C and S11C). Anxiety-like behavior
assessed by the elevated plus maze showed no significant changes
in the total number of entries (Figs. S10D and S11D), entries
into the open arms (Figs. S10E and S11E), and time spent in the
dark and light arms and center of the maze (Figs. S10F and
S11F) in all of the mice tested. Results from the passive avoidance
paradigm showed that NMDA, EHD2–scTNFR2, and ATROSAB
did not result in differences of the preshock latency to enter the
dark compartment in the hu/mTNFR2-k/i mice (Fig. 3B) and
hu/mTNFR1-k/i mice (Fig. 3D). However, NBM injection of
NMDA caused a significant impairment in the postshock latency
in all of the mice tested (Fig. 3 C and E). Both EHD2–scTNFR2
and ATROSAB obliterated NMDA-mediated memory impair-
ment (Fig. 3 C and E). EHD2–scTNFR2 and ATROSAB when
given without NMDA had no effect on postshock latency (Fig. 3 C
and E). These results indicate the lack of neurotoxicity of EHD2–
scTNFR2 and ATROSAB and accentuate their protective effects
against NMDA toxicity.
Emergence of Neuroprotective TNFR2 Signaling in Vitro and in Vivo upon
ATROSAB-Mediated Inhibition of TNFR1.Previously we have shown that
the PI3K–PKB/Akt pathway mediates TNFR2-promoted neuro-
protection from excitotoxic cell death (10, 15, 16). To investigate
the molecular pathways underlying the neuroprotective effects of
ATROSAB, we isolated primary neurons from hu/mTNFR1-k/i
mice and investigated TNF-induced phosphorylation of PKB/Akt
(Ser473). As expected, stimulation with a nonreceptor- selective
wild-type mouse variant of EHD2–scTNFR2, with tmTNF-mimetic
activity (EHD2-sc–mTNF), induced phosphorylation of PKB/Akt.
Interestingly, phosphorylation was enhanced in the presence of the
TNFR1 antagonist ATROSAB (Fig. 4A), suggesting that PKB/Akt
activation occurs via TNFR2, and concomitant TNFR1 signaling
interferes with this pathway. In addition, TNF was shown to protect
primary neurons from glutamate-induced cell death in a TNFR2-
dependent manner (15). Similarly, we could show that the mouse
TNFR2-specific variant (D135N/A137R; 13) of the human TNFR2-
selective EHD2–scTNFR2 (EHD2-sc–mTNFR2) protects primary
hu/mTNFR1-transgenic neurons from excitotoxic cell death (Fig.
4B). In accordance with ATROSAB-mediated increase of PKB/Akt
phosphorylation, ATROSAB enhanced the neuroprotective effect
of EHD-sc–mTNF at lower concentrations (10 ng/mL; Fig. 4B) in
this in vitro cell model, too.
To prove the essential role of TNFR2 signaling in the in vivo
NBM lesion model, we simultaneously injected NMDA, ATROSAB,
and the mouse TNFR2-specific antagonist MAB426 (Fig. 4 C–F)
into hu/mTNFR1-k/i mice. Under these conditions, the protective ef-
fect of ATROSAB on both cholinergic innervation and macrophage/
microglial activation was completely reverted.
Fig. 3. EHD2–scTNFR2 and ATROSAB attenuate NMDA-induced memory
impairment. (A) A graphical description for the sequence of behavioral and
memory assessments in hu/mTNFR1-k/i (B and C) and hu/mTNFR2-k/i (D and
E) mice. Assessment of long-term memory with the passive avoidance par-
adigm showed no significant differences in (B and D) preshock latency be-
tween the experimental groups. NBM injection of NMDA caused a significant
impairment of long-term memory, measured as postshock latency, which
was obliterated by cotreatment of (C) EHD2 B and C scTNFR2 or (D) ATROSAB.
Error bars indicate ±SEM. *P < 0.05, **P < 0.01, one-way ANOVA with post
hoc comparisons Tukey.
Fig. 2. EHD2–scTNFR2 and ATROSAB prevent NMDA-induced NBM lesion and
macrophage/microglia activation. (A–D) hu/mTNFR2-k/i and (E–H) hu/mTNFR1-k/i
mice were used. (A and E) Representative images show choline acetyl-
transferase (ChAT)-positive cholinergic innervations in the somatosensory
cortex. NMDA injected into the NBM induced an extensive cholinergic fiber
loss in the layer V of somatosensory cortex compared with the control group.
However, EHD2–scTNFR2 or ATROSAB treatment attenuated fiber loss. Parallel
bars in indicate the layer V of the somatosensory cortex in which quantitative
measurements were performed. (B and F) Quantification of cholinergic fiber
density in layer V of the somatosensory cortex. Fiber density was measured in
eight sections per mouse, n = 7 mice per group. All data in bar charts represent
means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.0001, one-way ANOVA with post
hoc comparisons Tukey. (C and G) Representative images show CD11B-positive
activated macrophage/microglia in magnocellular nucleus basalis. NMDA injected
into the NBM induced a massive volume of macrophage/microglial activation,
compared with those in both control groups. However, EHD2–scTNFR2 or ATR-
SOAB treatment significantly reduced macrophage/microglial activation induced
by NMDA. (D and H) Quantification of total extent of activated macrophage/
microglia around the injections. Macrophage/microglial activation was measured
in a series of sections with macrophage/microglial activation, n = 7 mice per
group. All data in bar charts represent means ± SEM. *P < 0.05, **P < 0.01,
***P < 0.0001, one-way ANOVA with post hoc comparisons Tukey.









TNF can exert opposite effects via its two receptors, TNFR1 and
TNFR2. This dual role of TNF signaling becomes particularly
obvious in the central nervous system (5, 6). Using the cuprizone-
induced mouse model of demyelination, it was shown that
TNFR2 is critical for oligodendrocyte regeneration, whereas
TNF signaling via TNFR1 promoted nerve demyelination (9).
Similar, investigations in a mouse model of retinal ischemia
revealed that TNFR1-deficient animals were protected from is-
chemic lesions. In contrast, TNFR2−/− mice showed enhanced
neuronal loss and a more severe pathology compared with wild-
type animals, indicating an antagonistic function of the two
TNFRs. In the retinal ischemia model, TNFR2’s neuroprotective
activity in vivo was associated with PI3K-PKB/Akt activation,
which was counterbalanced by the neurodegenerative action of
TNFR1 (10). The same principle applied to cortical neurons,
where TNFR2 mediated in vitro protection from glutamate-
induced cell death in a PI3K-PKB/Akt-dependent manner (15,
16). We here show in an in vivo model of NMDA-induced cel-
lular degeneration and loss of neuronal functions that both a
TNFR2 selective agonist (EHD2–scTNFR2) and a TNFR1 an-
tagonistic antibody (ATROSAB) protect from loss of cholinergic
fibers and associated neurologic deficits.
Exacerbated activation of glutamate receptor-coupled calcium
channels and subsequent increase in intracellular calcium concen-
trations ([Ca2+]i), followed by sustained disturbances in the [Ca
2+]i
homeostasis, are established hallmarks of neuronal cell death in
acute and chronic neurological diseases (29, 30). Interestingly, ac-
tivation of potassium intermediate/small conductance calcium-
activated channel KCa2 prevented [Ca
2+]i deregulation and reduced
neuronal death following glutamate toxicity and cerebral ischemia
(31). We previously demonstrated that the neuroprotective effect
of TNFR2 against a glutamate challenge was associated with an
increased expression of KCa2.2 channels (16), outlining a potential
molecular mechanism of TNFR2-mediated protection of neurons
from death during exposure of a priori excitotoxic stimuli.
Studies on lovastatin actions further support TNFR2 involvement
in neuroprotection. Lovastatin is a cholesterol-lowering drug with
reported neuroprotective properties that can reduce the incidence
of stroke and progression of Alzheimer’s disease. Lovastatin in-
creased the expression of TNFR2 in cortical neurons in vitro (32)
and was neuroprotective in TNFR1−/−neurons, whereas lovastatin’s
protection was lost in neurons from TNFR2−/− mice (32). Fur-
thermore, lovastatin-mediated neuroprotection led to an increase in
PI3K-dependent PKB/Akt phosphorylation, whereas inhibition of
PKB/Akt activation entirely abolished lovastatin-induced neuro-
protection. This finding is in line with previous findings that TNFR2-
mediated neuroprotection is dependent on the PI3K-PKB/Akt
pathway (15), and suggests that lovastatin-induced neuroprotection
is dependent on TNFR2 signaling. Administration of lovastatin
protected cholinergic neurons and their cortical projections against
NMDA-induced excitotoxic damage in vivo (23). Furthermore,
treatment with the PI3K inhibitor LY294002 to block activation of
PKB/Akt resulted in a strong reduction of lovastatin-mediated
neuroprotection (23).
In the present report, we evaluated the therapeutic potential of
the TNFR2 agonist EHD2–scTNFR2 and the TNFR1 antagonistic
antibody ATROSAB in this mouse model of NMDA-induced
neurodegeneration. Similar to lovastatin, both EHD2–scTNFR2 and
ATROSAB reduced the extent of areas of macrophage/microglia
activation at the site of the lesion and protected cholinergic neurons
and the neocortical innervations against NMDA-induced excito-
toxic damage. Functional consequences of NMDA-induced lesions
and the therapeutic activity of TNFR targeting reagents became
phenotypically apparent in behavioral performance studies: damage
to the NBM selectively affected neocortical cholinergic denervation
and its memory functions, while leaving particular hippocampal
innervation and functions unaffected. Treatment of such animals
with either EHD2–scTNFR2 or ATROSAB fully restored the af-
fected cholinergic memory function.
ATROSAB-induced protection from excitotoxicity induced neu-
rodegeneration was found to be linked to an enhancement of TNFR2
signaling leading to PKB/Akt activation; this is evident from abroga-
tion of neuroprotection in vivo upon cotreatment with TNFR2
blockers and from in vitro studies showing increased phosphorylation
of PKB/Akt as well as enhanced resistance of primary cortical neurons
toward excitotoxic insult by a tmTNFmimetic TNF in the presence of
a TNFR1 blockade. We propose that the neuroprotective activity of
ATROSAB is accomplished by simultaneous action on two different
cellular targets: (i) as a consequence of the excitotoxic insult, activated
Fig. 4. ATROSAB is neuroprotective via enhanced TNFR2 signaling. (A) Primary
neurons, isolated from hu/mTNFR1-k/i mice, were stimulated with or without
ATROSAB (100 μg/mL) for 30 min followed by addition of wild-type EHD2-sc–mTNF
(10 ng/mL). Then cells were incubated for 24 h and lyzed, and phosphorylation of
PKB/Akt was quantified byWestern blot (n= 4,±SEM). (B) Primary neurons, isolated
from hu/mTNFR1-k/i mice, were stimulated with or without ATROSAB (100 μg/mL)
for 30 min followed by addition of non–TNFR-selective EHD2-sc–mTNF or mouse
TNFR2-selective EHD2-sc–mTNFR2. After 24 h, glutamate (5 μM) was added and
cells were incubated for an additional hour. Then medium was exchanged to
remove glutamate and cells were incubated for 23 h. Cell viability was de-
termined by MTT assay. Data are shown as percentage of MTT signal of
untreated control cells (n = 3; ±SEM). Representative images show (C) ChAT-
positive cholinergic innervations in the somatosensory cortex or (E) CD11B-
positive activated macrophage/microglia in magnocellular nucleus basalis.
NMDA injected into the NBM induced an extensive cholinergic fiber loss in
the layer V of somatosensory cortex and a massive volume of macrophage/
microglial activation compared with the control group. However, ATROSAB
treatment attenuated fiber loss and significantly reduced macrophage/
microglial activation induced by NMDA. ATROSAB neuroprotection against
fiber loss was prevented by TNFR2 antagonistic MAB426. However, MAB426
alone did not significantly alter NMDA-induced NBM lesion. Parallel bars
indicated the layer V of the somatosensory cortex in which quantitative
measurements were performed. (D) Quantification of cholinergic fiber
density in layer V of the somatosensory cortex. Fiber density was measured
in eight sections per mouse. (F) Quantification of total extent of activated
macrophage/microglia around the injections. Macrophage/microglial activation
was measured in a series of sections with macrophage/microglial activation. n = 7
mice/group. All data in bar charts represent means ± SEM. *P < 0.05, **P < 0.01,
***P < 0.0001, one-way ANOVA with post hoc comparisons Tukey.
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macrophage/microglia promote, via soluble TNF production, the ex-
pansion of the degenerative tissue response in an autocrine TNFR1-
dependent way; and (ii) inhibition of TNFR1 limits this process
both at the level of microglia/macrophage activation and at
the level of neurons of TNFR1-mediated degenerative sig-
naling. Further, for neuronal cells, it was shown previously
that proper TNFR2 activation induces protection from exci-
totoxicity in vitro (15, 16); in the in vivo model analyzed here,
in neurons in the vicinity of the acute insult and not immedi-
ately succumbing to excitotoxic death, competition of TNFRs
for limiting amounts of endogenously produced membrane
form of TNF exists, which results in suboptimal activation of
TNFR2 of this cell population under a nontreatment condi-
tion. Moreover, at the level of intracellular signaling, it is
known that signal cross-talk between TNFR1 and 2 exists in
terms of competition for common signal transducers such as
TRAF2 (33–35), with TNFR1 outperforming TNFR2 path-
ways in the case of abundance of soluble TNF, which triggers
exclusively TNFR1 (3, 6). In the presence of ATROSAB,
neuronal response is shifted toward neuroprotective TNFR2
signaling because of blocked neuronal TNFR1, allowing the
induction of a resistant state by endogenous tmTNF (Fig. 5).
The therapeutic activity of TNFR2 activation by treatment
with EHD2–scTNFR2 without interfering with TNFR1 sig-
naling supports the view of limited TNFR2 activation by en-
dogenous TNF. Accordingly, TNFR2’s role as an important
neuroprotective pathway emerges when TNFR1 ligand bind-
ing is stalled and/or when TNFR2 activation is optimized by
application of exogenous TNFR2-selective ligands.
Importantly, initial studies with anti-TNF therapeutics showed
that TNF blocking drugs cannot be used to treat neurodegener-
ative diseases such as MS. In support of this finding, we here
provide compelling evidence in an in vivo model of NMDA-
induced acute neuronal lesions that abrogation of complete TNF
signaling by blocking both TNFRs is not protective, because
mounting of a neuroprotective TNFR2-dependent response
is prevented. However, preclinical studies in the experimen-
tal autoimmune encephalomyelitis (EAE) model (36–38) or a
mouse model of spinal cord injury (39) revealed that selective
neutralization of sTNF/TNFR1 signaling is neuroprotective.
Of note, in the EAE model, systemic application of TNFR1-
blocking antibodies proved to be therapeutically effective (40).
Accordingly, TNFR1 antagonists such as ATROSAB should be
superior to conventional anti-TNF drugs in the treatment of neuro-
degenerative diseases, as they spare TNFR2 and even enhance
TNFR2 signaling but still block detrimental signals transmitted via
TNFR1. In addition to the potential therapeutic use of TNFR1-
specific antagonistic antibodies, TNFR2-selective agonists seem to be
particularly suitable to treat inflammatory, demyelinating diseases,
because next to the direct neuroprotective effects shown in this re-
port, data from different laboratories outline that TNFR2 is also
involved in immune suppression via expansion and stabilization of
regulatory T cells (41–47), and induces remyelination (9, 13, 14).
Thus, like TNFR1 antagonists, TNFR2 agonists might promote
therapeutic effects via multiple cellular targets. Limiting for the
treatment of neurodegenerative diseases is the blood–brain–barrier
(BBB), which restricts the transport of therapeutics into the CNS.
Under physiologic conditions, antibodies, e.g., ATROSAB, do not
cross the BBB. However, of relevance, the BBB undergoes rapid
changes in permeability in response to CNS insults, e.g., after spinal
cord injury or during MS, potentially enabling therapeutics to reach
the CNS parenchyma without specific transport mechanisms. Indeed,
the reported therapeutic activity of ATROSAB in EAE models (40)
supports this reasoning. Whether alterations of the BBB permeability
in different neurodegenerative diseases are sufficient to reach ther-
apeutic effective concentrations in the CNS is presently unclear.
Therefore, strategies are now available to overcome limits of BBB
passage. Thus, antibodies engineered to be actively transported via
BBB have been developed that were shown to be beneficial for the
treatment of Alzheimer’s disease (48, 49). Cytokines including TNF
can cross the BBB (50). By analogy, we assume that the engineered
TNF mutein EHD2–scTNFR2 could be able to penetrate the
BBB, too.
In summary, in an acute neurodegenerative disease model, we
provide proof of concept that both the TNFR2-selective TNF
variant EHD2–scTNFR2 and the antagonistic TNFR1-selective
antibody ATROSAB protect from neurological deficits due to
excitotoxic cell death induced by excessive glutamate exposure
in vivo. Our data provide a rational base for previous failure of
clinical studies with anti-TNF drugs in neurodegenerative diseases
and highlight the essential protective role of TNFR2 in the central
nervous system. Further investigations in additional neurodegen-
erative diseases models on the therapeutic potential of the TNFR2
agonist EHD2–scTNFR2 and the TNFR1 antagonist ATROSAB
are warranted and will reveal whether and for which indications
these or functionally similar proteins can be successfully applied.
Materials and Methods
Detailed methods can be found in SI Materials and Methods. The TNFR2 agonist
EHD2–scTNFR2 and the tmTNF-mimetic TNF mutein EDH2–scTNF are described in
this work. The transgenic hu/mTNFR-k/i mice were generated as contracted by
Ozgene Pty Ltd. Animal care and treatment were carried out in accordance with
Committee Groningen (Dierexperimenten Comissie Van de Rijksuniversiteit Gro-
ningen) and Committee Stuttgart (Regierungspräsidium Stuttgart) guidelines on
the use of experimental animals at the University of Groningen (permit no.
DEC6523) and theUniversity of Stuttgart (permit no. 35-9815.81-0350), respectively.
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